The utilization and challenges of Japan's MID‐NET ® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies-Reference-Cited by-同舟云学术

The utilization and challenges of Japan's MID‐NET ® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies

Published:2019-04-03 Issue:5 Volume:28 Page:601-608
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Yamada Kaori¹,Itoh Maori¹,Fujimura Yoshiaki²,Kimura Michio³,Murata Koichiro⁴,Nakashima Naoki⁵,Nakayama Masaharu⁶,Ohe Kazuhiko⁷,Orii Takao⁸,Sueoka Eizaburo⁹,Suzuki Takahiro¹⁰,Yokoi Hideto¹¹,Ishiguro Chieko¹^ORCID,Uyama Yoshiaki¹^ORCID,

Affiliation:

1. Office of Medical Informatics and EpidemiologyPharmaceuticals and Medical Devices Agency Tokyo 100‐0013 Japan

2. Head OfficeTokushukai Information System Incorporated Osaka Japan

3. Department of Medical InformaticsHamamatsu University Hospital Shizuoka Japan

4. Department of RadiologyKitasato University Hospital Kanagawa Japan

5. Department of Advanced Information TechnologyKyushu University Hospital Fukuoka Japan

6. Medical InformaticsTohoku University Graduate School of Medicine Miyagi Japan

7. Department of Healthcare Information ManagementThe University of Tokyo Hospital Tokyo Japan

8. Department of PharmacyNTT Medical Center Tokyo Tokyo Japan

9. Department of Laboratory MedicineSaga University Hospital Saga Japan

10. Department of Medical InformaticsChiba University Hospital Chiba Japan

11. Department of Medical InformaticsKagawa University Hospital Kagawa Japan

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4777

Reference23 articles.

1. Real-World Evidence — What Is It and What Can It Tell Us?

2. The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety

3. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

4. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan

5. The FDA's sentinel initiative-A comprehensive approach to medical product surveillance

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage;Pharmacoepidemiology and Drug Safety;2024-09

2. Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ^® in Japan;Journal of Dermatological Treatment;2024-07-04

3. Increased risk of hypocalcemia with decreased kidney function in patients prescribed bisphosphonates based on real-world data from the MID-NET® in Japan: a new-user cohort study;BMC Nephrology;2024-04-15

4. Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan;PLOS ONE;2024-01-26

5. Prescription trend and lactic acidosis in patients prescribed metformin before and after the revision of package insert for allowing metformin administration to patients with moderately decreased kidney function based on real-world data from MID-NET® in Japan;Frontiers in Medicine;2024-01-24